Chipotle 2012 Annual Report Download - page 77

Download and view the complete annual report

Please find page 77 of the 2012 Chipotle annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 136

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136

INFORMATION REGARDING THE BOARD OF DIRECTORS
Biographical Information
The following is biographical information about each of the three nominees and each other current director,
including a description of the experience, qualifications and skills that have led the Board to determine that each
director should serve on the Board. The respective current terms of all directors expire on the dates set forth
below or continue until their successors are elected and have qualified.
Class II directors whose terms expire at the
2013 annual meeting of shareholders and
who are nominees for terms expiring at the
2016 annual meeting Age
Director
Since
Albert S. Baldocchi .............. Mr.Baldocchihasbeenself-employed since 2000 as a
financial consultant and strategic advisor for and investor
in a variety of privately-held companies. His extensive
involvement with restaurant companies over a period of 17
years has given Mr. Baldocchi an in-depth knowledge of
restaurant company finance, operations and strategy. He
also has considerable experience with high-growth
companies in the restaurant industry and in other industries,
and his experience as a senior investment banker at a
number of prominent institutions, including Morgan
Stanley, Solomon Brothers and Montgomery Securities,
helped him develop solid capabilities in accounting and
finance as well. Mr. Baldocchi holds a Bachelor of Science
degree in chemical engineering from the University of
California at Berkeley and an MBA from Stanford
University.
58 1997
Neil W. Flanzraich .............. Mr.Flanzraich has been a private investor since February
2006, and as an executive board member, also runs a
number of privately-owned pharmaceutical companies.
From 1998 through its sale in January 2006 to TEVA
Pharmaceuticals Industries, Ltd., he served as Vice
Chairman and President of IVAX Corporation, an
international pharmaceutical company. From 1995 to
1998, Mr. Flanzraich served as Chairman of the Life
Sciences Legal Practice Group of Heller Ehrman LLP, a
law firm, and from 1981 to 1994, served in various
capacities at Syntex Corporation, a pharmaceutical
company. Mr. Flanzraich’s executive experience has
helped him develop outstanding skills in leading and
managing strong teams of employees, and in oversight of
the growth and financing of businesses in a rapidly-
evolving market. His legal background also is valuable to
us in the risk management area, and Mr. Flanzraich brings
to us extensive experience serving as an independent
director of other public and privately-held companies. He
is a director of Equity One Inc. (NYSE:EQY). Mr.
Flanzraich was a director of BELLUS Health Inc. until
May 2012, a director of Continucare Corporation until
October 2011, a director of Javelin Pharmaceuticals, Inc.
until July 2010, and a director of RAE Systems, Inc. until
March 2009. Mr. Flanzraich received an A.B. from
Harvard College and a J.D. from Harvard Law School.
69 2007
7
Proxy Statement